Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Immunotherapy: Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy, cartea 5
Editat de Kasuya Hideki, Itzel Bustos Villalobosen Limba Engleză Hardback – 31 oct 2024
- Discusses oncolytic virus in pancreatic cancer use, mainly herpes and adenoviruses, the results obtained on basic research, and clinical trials
- Encompasses knowledge on Bi-specific T cell engager (BiTEs), focusing on its function, development and use on pancreatic cancer
- Brings information on recently developed combination therapies that allow for a lower dose of treatment and hence less side effects
Preț: 798.05 lei
Preț vechi: 1030.44 lei
-23% Nou
Puncte Express: 1197
Preț estimativ în valută:
152.73€ • 158.65$ • 126.86£
152.73€ • 158.65$ • 126.86£
Carte disponibilă
Livrare economică 06-20 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780128229149
ISBN-10: 0128229144
Pagini: 250
Dimensiuni: 191 x 234 mm
Editura: ELSEVIER SCIENCE
Seria Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy
ISBN-10: 0128229144
Pagini: 250
Dimensiuni: 191 x 234 mm
Editura: ELSEVIER SCIENCE
Seria Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy
Cuprins
1. Pancreatic cancer generalities, current surgical treatment, updates
2. Current chemotherapy and immunotherapy in pancreatic cancer
3. Generalities of Oncolytic virus and HF10 in pancreatic cancer
4. Oncolytic Adenovirus use in pancreatic cancer
5. BiTE cell generalities and its potential use for pancreatic cancer
6. Precision oncology for pancreatic cancer
7. Strategies with immune therapy
8. Combination therapies of current/ new options to treat pancreatic cancer in future
2. Current chemotherapy and immunotherapy in pancreatic cancer
3. Generalities of Oncolytic virus and HF10 in pancreatic cancer
4. Oncolytic Adenovirus use in pancreatic cancer
5. BiTE cell generalities and its potential use for pancreatic cancer
6. Precision oncology for pancreatic cancer
7. Strategies with immune therapy
8. Combination therapies of current/ new options to treat pancreatic cancer in future